key: cord-0695916-6zu6qjcu
authors: Gagne, Matthew; Corbett, Kizzmekia S.; Flynn, Barbara J.; Foulds, Kathryn E.; Wagner, Danielle A.; Andrew, Shayne F.; Todd, John-Paul M.; Honeycutt, Christopher Cole; McCormick, Lauren; Nurmukhambetova, Saule T.; Davis-Gardner, Meredith E.; Pessaint, Laurent; Bock, Kevin W.; Nagata, Bianca M.; Minai, Mahnaz; Werner, Anne P.; Moliva, Juan I.; Tucker, Courtney; Lorang, Cynthia G.; Zhao, Bingchun; McCarthy, Elizabeth; Cook, Anthony; Dodson, Alan; Mudvari, Prakriti; Roberts-Torres, Jesmine; Laboune, Farida; Wang, Lingshu; Goode, Adrienne; Kar, Swagata; Boyoglu-Barnum, Seyhan; Yang, Eun Sung; Shi, Wei; Ploquin, Aurélie; Doria-Rose, Nicole; Carfi, Andrea; Mascola, John R.; Boritz, Eli A.; Edwards, Darin K.; Andersen, Hanne; Lewis, Mark G.; Suthar, Mehul S.; Graham, Barney S.; Roederer, Mario; Moore, Ian N.; Nason, Martha C.; Sullivan, Nancy J.; Douek, Daniel C.; Seder, Robert A.
title: Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway
date: 2021-10-24
journal: bioRxiv
DOI: 10.1101/2021.10.23.465542
sha: cb9309f857702b0dcc290afdc9f69c6511594552
doc_id: 695916
cord_uid: 6zu6qjcu

mRNA-1273 vaccine efficacy against SARS-CoV-2 Delta wanes over time; however, there are limited data on the impact of durability of immune responses on protection. We immunized rhesus macaques at weeks 0 and 4 and assessed immune responses over one year in blood, upper and lower airways. Serum neutralizing titers to Delta were 280 and 34 reciprocal ID50 at weeks 6 (peak) and 48 (challenge), respectively. Antibody binding titers also decreased in bronchoalveolar lavage (BAL). Four days after challenge, virus was unculturable in BAL and subgenomic RNA declined ∼3-log10 compared to control animals. In nasal swabs, sgRNA declined 1-log10 and virus remained culturable. Anamnestic antibody responses (590-fold increase) but not T cell responses were detected in BAL by day 4 post-challenge. mRNA-1273-mediated protection in the lungs is durable but delayed and potentially dependent on anamnestic antibody responses. Rapid and sustained protection in upper and lower airways may eventually require a boost.

mRNA-1273 and mRNA control NHP were challenged 49 weeks after the initial immunization 277 with 2x10 5 plaque forming units (PFU) of virus via intratracheal (IT) and intranasal (IN) routes 278 (Fig. S1A ). BAL and nasal swabs (NS) were collected on days 2, 4, 7 and 14 following challenge 279 and qRT-PCR was used to measure viral replication by assessing sgRNA copies encoding for the 280 SARS-CoV-2 E and N genes. On day 2, geometric mean sgRNA_E copies in the lower airway of 281 controls and vaccinated NHP were 1x10 6 and 9x10 4 per mL, respectively (P>0.05) (Fig. 6A) . 282 sgRNA_E copies in the lower airway of vaccinated NHP declined rapidly over the following 283 days, with geometric mean copies of 9x10 2 on day 4 and 1x10 2 on day 7. sgRNA_E copies in the 284 lungs of unvaccinated NHP remained significantly elevated compared to vaccinated NHP, with a 285 geometric mean of 1x10 5 on day 7 (mRNA-1273 vs control: P<0.0001). These results differed 286 from our earlier findings that NHP vaccinated with 100µg mRNA-1273 and then challenged only In contrast to the lower airway, we observed less reduction in viral replication in the upper 291 airway following mRNA-1273 immunization (Fig. 6B ). On day 2, geometric mean copies of 292 sgRNA_E were 2x10 6 and 6x10 4 per NS of controls and vaccinated NHP, respectively 293 (P=0.0038). On days 4 and 7, copies declined to 2x10 3 and 1x10 3 for the mRNA-1273 group and 294 4x10 5 and 5x10 4 in the control group (Day 4: P=0.006; Day 7: P>0.05). By day 7, 6/8 and 4/8 295 vaccinated NHP had undetectable sgRNA_E levels in the lower airway and upper airway, 296 respectively. All control NHP still had detectable sgRNA_E copies at that time point. We 297 observed similar trends with sgRNA_N ( Fig. 6C-D) , but with higher geometric mean copy 298 numbers in agreement with our prior publications (Corbett et al., 2021b; Corbett et al., 2021c) . 299

We euthanized 4/8 NHP in each cohort on day 7 for assessment of lung pathology but continued 300 to monitor the remaining animals for an additional week. On day 14, 1/4 and 2/4 control NHP 301 had detectable sgRNA_N in the lower and upper airway, respectively. In contrast, 0/4 and 1/4 302 vaccinated NHP had detectable sgRNA_N in the same compartments. It is noteworthy that the 303 only animal in the mRNA-1273 cohort with detectable sgRNA_N at day 14 had undetectable 304 pseudovirus neutralizing antibody titers to both D614G and B.1.617.2 at week 48 (Fig. 1F) . week 48 and was higher than WA1 GMT at day 14. In contrast, B.1.617.2 GMT in the mRNA-332 1273 group increased only 490-fold at day 14 relative to week 48 and was equivalent to WA1 333 GMT at that time. In addition, WA1 S-2P binding GMT in control NHP increased 39-fold from 334 0.9 BAU/mL to 35 BAU/mL between week 48 after immunization and day 14 after challenge. 335

The corresponding increase in vaccinated NHP was smaller, rising 5-fold from 189 to 1030 336 BAU/mL (Fig. 1A) . 337 338 Pseudovirus neutralizing responses were also measured to D614G and B.1.617.2 at days 2, 4, 7 339 and 14. The hierarchy of neutralizing antibody titers elicited by the vaccine remained stable until 340 day 14, when titers to B.1.617.2 approached those of D614G (P>0.05) (Fig. 1F ). These findings 341

show that while serum antibody responses did not increase at a faster rate in vaccinated NHP 342 than in controls, they were boosted by infection. Fig S2) . Last, we did not detect differential IgA responses or ACE2 binding 355 inhibition between vaccinated animals or controls in either the lower or upper airway ( Fig. 3E-H  356 and Fig S2) . These data show that the mRNA-1273-vaccinated NHP made an anamnestic IgG 357 response in the lower airways. 358

Although the total IgG concentration in the lungs of both vaccinated and unvaccinated NHP 360 increased following challenge, this increase was greater in the control cohort. On days 2, 4, 7 and 361 14 after challenge, geometric mean IgG concentrations were 1.5-to 3-fold lower in the 362 vaccinated cohort than in the control group (Fig. S7A ). This rapid response after challenge is 363 consistent with our prior experience of a protein SARS-CoV-2 vaccine in which we observed a 364 rapid increase in both total IgG and measles morbillivirus (MeV) titers in primates that had also 365 been vaccinated against MeV (Francica et al., 2021). In the present study, although binding titers 366

were similar between both cohorts prior to challenge, responses to MeV increased more rapidly in the control group. On day 4, GMT to MeV in the lower airway were 3.3-fold greater in the 368 control animals than in the mRNA-1273 group (Fig. S7B) . 369 370 An anamnestic S-specific B cell response in the lower airways would likely be the underlying 371 mechanism for an increase in local antibody titers. While we were unable to collect a sufficient 372 number of B cells in BAL to analyze after B.1.617.2 challenge, we were nevertheless able to 373 interrogate these cells in blood. Memory B cells which bound both WA1 S-2P and B.1.617.2 S-374 2P dominated the S-specific immune response of vaccinated NHP. While the total frequency of 375 all S-binding memory B cells increased, the proportion of these dual-specific cells remained 376 between 85-90% (Fig. 4E ). In contrast, B.1.617.2 challenge in control NHP elicited a higher 377 frequency of memory B cells specific only for B.1.617.2 S, with a geometric mean frequency of 378 57% at day 28 ( Fig 4E) . 72% of S-binding B cells in control NHP had a phenotype consistent 379 with activated memory B cells, in contrast to the vaccinated cohort in which 49% of cells had an 380 activated memory phenotype and 38% of cells had a resting memory phenotype (Fig. 4F) . 381 382 T cell responses in blood and BAL following vaccination and B.1.617.2 challenge 383

After showing a potential role for memory B cell responses in controlling virus replication in 384 lower airways, we also measured T cell responses to SARS-CoV-2 S in the blood and BAL 385 following challenge. By day 7, TH1 responses were elevated as compared to week 42 in both 386 compartments (Serum: P=0.0199; BAL: P=0.0097). However, the range of S-specific TH1 CD4 + 387 T cell frequencies in the BAL of control and vaccinated NHP overlapped (Fig. 5A , F). While we 388 observed increased IL-21 + TFH responses by day 7 (P=0.0061) (Fig. 5E ), we did not detect any 389 TH2 responses following challenge in vaccinated or control animals (P>0.05) (Fig. 5B, G) . In 390 contrast to the minimal vaccine-elicited CD8 + T cells prior to challenge, both control and 391 vaccinated NHP mounted CD8 + T cell responses following challenge (Fig. 5C, H) . Finally, TH1 392 and CD8 + responses in the lungs to SARS-CoV-2 N, which was not encoded by mRNA-1273, 393

were only present in control NHP (Fig. S4 ). Together, these data demonstrate that vaccination 394 with mRNA-1273 not only elicited B and T cellular responses to SARS-CoV-2 S following 395 challenge but also protected NHP from encountering sufficient levels of SARS-CoV-2 N to 396 mount a primary response to that antigen. Changes in control NHP were more consistent with lymphocytes, histiocytes and fewer 411 polymorphonuclear cells associated with more prominent and expanded alveolar capillaries, 412 collections of cells with alveolar air spaces, occasional areas of perivascular and peribronchiolar 413 inflammation, and Type II pneumocyte hyperplasia (Fig. 7B ). The protection observed in the 414 lungs suggest that although binding and neutralizing antibody titers had declined one year after 415 vaccination ( Fig. 1) , leaving the lower airway susceptible to virus replication in the first two days 416 after challenge (Fig. 6) , a local anamnestic response to antigen previously encountered in the 417 vaccine proved sufficient to prevent severe disease. the pre-challenge timepoint, and there was no detectable sgRNA_E in 6/8 vaccinated NHP by 452 day 7. This suggests that protection in the lower airway is durable but somewhat delayed and 453 may be dependent on a recall antibody response. It is also notable that while we were able to 454 detect binding and some functional antibodies in the blood and mucosa through the S-2P-ACE2 455 inhibition assay at time of challenge, neutralizing titers to B.1.617.2 were low to undetectable. 456

Thus, vaccine-elicited protection in the lower airway could be mediated by neutralizing 457 antibodies below our limit of detection or through Fc-mediated functions, which has been shown 458 to be important for protection by mAb treatment (Winkler et al., 2021) . It is also noteworthy that although the quantity of antibodies had decreased one year after vaccination, the quality was Here we show that S-specific T cells decreased over the course of one year but were still 498 detectable in a subset of vaccinated NHP at the time of challenge. A second potential role for T 499 cells would be mediating control of viral replication in the lower airway to limit severe disease. 500

Notably, we did not see increased TH1 or CD8 + T cell responses in the BAL of vaccinated NHP 501 compared to controls following challenge. Interestingly, we detected CD8 + T cells in the blood 502 before detection in the lungs post-challenge, which requires further investigation. Formal 

Determination of antibody responses in the blood and mucosa were performed as previously 569 described for measurement of mucosal antibody responses (Corbett et al., 2020) . Briefly, heat 570 inactivated plasma was serially diluted 1:4. BAL fluid and nasal washes were concentrated 10-571 fold with Amicon Ultra centrifugal filter device (Millipore Sigma) and then serially diluted 1:5. 572

Total IgG and IgA antigen-specific antibodies to variant SARS-CoV-2 RBD-derived antigens 573

were determined by enzyme-linked immunosorbent assay (ELISA) using MULTI-ARRAY 384-574 well streptavidin-coated plates (Meso Scale Discovery, MSD). Plates were coated with variant-575 specific biotinylated antigens (see Table S1 ) at a concentration of 0.18μg/mL. MSD plate reader 576 Pseudotyped lentiviral reporter viruses were produced as previously described (Wu et al., 2021) . Previously isolated and cryopreserved PBMC were centrifuged into warm RPMI/10% FBS and 662 resuspended in wash buffer (4% heat inactivated newborn calf serum/0.02% NaN3/ phenol-free 663 RPMI). PBMC were transferred to 96-wells, washed twice in 1X PBS, and incubated with Aqua 664

Blue live/dead cell stain (Thermo Fisher Scientific) at room temperature for 20 minutes. 

Post-challenge Post-immunization See also Table S1 for list of mutations in MULTI-ARRAY ELISA and Figure S1 for live virus neutralizing responses from individual NHP and experimental schematic. See also Table S2 for Barnes classifications of mAbs.

mRNA-1273 control 

Post-challenge 

Post-challenge See also Figure S5 for B.1.617.2 challenge stock characterization, Figure S6 and Table S3 for correlates analysis, and Figure S7 for non-specific immune responses following challenge. 

Efficacy and Safety of the mRNA-1273 SARS-CoV-2

Covid-19 in the Phase 3 Trial of mRNA-1273 During the 847 Delta-variant Surge. medRxiv

Durable Humoral and Cellular Immune Responses 8 850 Months after Ad26.COV2.S Vaccination

Covid-19 Breakthrough Infections in Vaccinated 853 Health Care Workers

TLR3 and TLR7 RNA Sensor Activation during SARS

CoV-2 Infection

Effectiveness of mRNA-1273 against Delta, Mu, and other 859 emerging variants. medRxiv

Significant reduction in humoral immunity among 862 healthcare workers and nursing home residents 6 months after COVID-19 BNT162b2 mRNA 863 vaccination. medRxiv

Waning of BNT162b2 Vaccine 866 Protection against SARS-CoV-2 Infection in Qatar

SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the 869 Second Wave of COVID-19 in Maharashtra

Serum Neutralizing Activity

CoV-2 Variants

Development and persistence of local and systemic 874 antibody responses in adults given live attenuated or inactivated influenza A virus vaccine

Evaluation of the mRNA-1273 Vaccine against 878 SARS-CoV-2 in Nonhuman Primates

Protection against SARS-CoV-2 Beta Variant 881 in mRNA-1273 Boosted Nonhuman Primates. bioRxiv

Changing composition of SARS-CoV-2 lineages 972 and rise of Delta variant in England

SARS-CoV-2 B.1.617.2 Delta variant replication and immune 975 evasion

Clinical and virological features of SARS-CoV-2 variants of concern: a 978 retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta)

SARS-CoV-2 D614G spike mutation increases entry efficiency with 982 enhanced ACE2-binding affinity

Rapid induction of antigen-specific CD4(+) T 985 cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA 986 vaccination

Nucleoside-modified mRNA vaccines induce 989 potent T follicular helper and germinal center B cell responses

Effectiveness of mRNA Covid-19 992 Vaccine among U.S. Health Care Personnel

Reduced sensitivity of SARS-CoV-2 variant 995 Delta to antibody neutralization

Safety and Efficacy of the BNT162b2 mRNA 998 Covid-19 Vaccine

SARS-CoV-2 infection generates tissue-localized 1001 immunological memory in humans

Comparison of two highly-effective mRNA 1004 vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv

Safety and immunogenicity of 1008 ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults 1009 (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Role of IgA versus IgG in the 1011 control of influenza viral infection in the murine respiratory tract

Functional SARS-CoV-2-1014 Specific Immune Memory Persists after Mild COVID-19

SARS-CoV-2 binding 1017 and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in 1018 rhesus macaques

S Vaccine against Covid-19

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the 1024 B.1.351 Variant

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector 1027 Vaccine against SARS-CoV-2 Variants. bioRxiv

COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar. medRxiv

SARS-CoV-2 mRNA vaccines induce persistent human 1034 germinal centre responses

ChAdOx1 nCoV-1037 19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Development of a Rapid Focus 1040 Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies

CCR2-dependent monocyte-derived cells 1044 restrict SARS-CoV-2 infection. bioRxiv

Airborne transmission of respiratory viruses

Ultrapotent antibodies against diverse and highly transmissible 1049 SARS-CoV-2 variants

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms 1052 and the ability to use ACE2 receptors from additional species

Naturally enhanced neutralizing breadth 1055 against SARS-CoV-2 one year after infection

mRNA vaccine-elicited antibodies to 1058 SARS-CoV-2 and circulating variants

SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border 1061 transmission of high risk variants into the United Kingdom

Human neutralizing antibodies against SARS-CoV-2 require intact Fc 1064 effector functions for optimal therapeutic protection

Serum Neutralizing Activity Elicited by 1067 mRNA-1273 Vaccine

CoV-2 in rhesus macaques. Nature 586, 583-588. 970